NasdaqGS - Nasdaq Real Time Price USD

Biogen Inc. (BIIB)

201.99

+8.81

(+4.56%)

At close: April 24 at 4:00 PM EDT

202.00

+0.01

(+0.00%)

Pre-Market: 4:36 AM EDT

Biogen stock rises on Q1 results, Alzheimer's drug sales

Shares of the biopharmaceutical company Biogen (BIIB) are on the rise Wednesday, buoyed by the company's first quarter results. The company beat profit expectations, driven by Biogen's cost-cutting initiatives and the boost in sales for its Alzheimer's drug, Leqembi. Yahoo Finance's Anjalee Khemlani breaks down the details of the report. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith

Yahoo Finance Video 18 hours ago

BIIB
+4.56%
Q1 2024 Biogen Inc Earnings Call

Q1 2024 Biogen Inc Earnings Call

Thomson Reuters StreetEvents 4 hours ago

BIIB
+4.56%
Why Biogen Stock Leaped Nearly 5% Higher Today

The company came out swinging with its first set of quarterly earnings for this year.

Motley Fool 11 hours ago

BIIB
+4.56%
^GSPC
Biogen Stock Surges After Two Notable Products Walloped Sales Expectations

Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and helped Biogen stock jump.

Investor's Business Daily 13 hours ago

BIIB
+4.56%
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings

On Wednesday, Biogen Inc (NASDAQ:BIIB) reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44. The company reported sales of $2.29 billion, down 7% year over year and missing the consensus of $2.31 billion. Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Multiple sclerosis drug Tysabri sales were down to $431.3 million from $472.8 million. Also Read: Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analys

Benzinga 15 hours ago

BIIB
+4.56%
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.

Zacks 16 hours ago

BIIB
+4.56%
Biogen (BIIB) Q1 2024 Earnings Call Transcript

BIIB earnings call for the period ending March 31, 2024.

Motley Fool 16 hours ago

BIIB
+4.56%
Biogen: Don’t expect any big acquisitions this year

While the company is eager to diversify, CEO Chris Viehbacher said that in the near-term any dealmaking would likely focus on collaborations and early-stage assets.

BioPharma Dive 17 hours ago

BIIB
+4.56%
Biogen Stock Rises After Earnings, Jump in Sales of Alzheimer’s Drug

Biogen stock moved higher after the biopharmaceutical company reported better-than-expected earnings and a hefty increase in sales of its Alzheimer’s drug. Biogen reported first-quarter adjusted earnings of $3.67 a share from revenue of $2.29 billion. Optimistic commentary from Biogen regarding its Alzheimer’s treatment Leqembi contributed to Wednesday’s gain.

Barrons.com 18 hours ago

BIIB
+4.56%
Biogen Affirms Guidance After Mixed First Quarter

Biogen Affirms Guidance After Mixed First Quarter

PREMIUM
MT Newswires 19 hours ago

BIIB
+4.56%
Alzheimer’s Drug Leqembi Sees Sales Pickup, Boosting Biogen Stock

Sales of a groundbreaking new Alzheimer’s disease treatment from Eisai and Biogen are finally accelerating, after a sluggish launch last year. Biogen said Wednesday that the number of patients taking the drug, Leqembi, has increased nearly 2 ½ times the levels at the end of 2023. It’s the first drug proven to slow the worsening of Alzheimer’s, but sales got off to a slow start because hospitals took longer than expected to set up systems to deliver the infused drug to patients.

The Wall Street Journal 19 hours ago

ESAIY

ESALF

BIIB
+4.56%
Biogen Beats Estimates as Alzheimer’s Drug Gains Traction

(Bloomberg) -- Biogen Inc. reported first-quarter profit that beat Wall Street’s expectations as the biotech giant’s new Alzheimer’s drug Leqembi gained traction and cost cuts took hold.Most Read from BloombergBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsTaylor Swift Is Proof That How We Critique Music Is BrokenBiden’s New Chopper Is Demoted After Scorching White House LawnTesla Soars as Musk’s Cheaper EVs Calm Fears Over StrategyAdjusted earnings for the quarter were

Bloomberg 19 hours ago

BIIB
+4.56%
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 19 hours ago

BIIB
+4.56%
Biogen Inc (BIIB) Q1 2024 Earnings: Mixed Results Amidst Strategic Growth Efforts

Despite Revenue Decline, Non-GAAP EPS Growth and Strategic Initiatives Show Promise

GuruFocus.com 20 hours ago

BIIB
+4.56%
Biogen sees ‘encouraging’ trends for postpartum depression drug

First quarter sales of Zurzuvae doubled consensus estimates, though analysts are skeptical whether the better-than-expected launch will continue.

BioPharma Dive 21 hours ago

BIIB
+4.56%
Biogen to invest more in launch of Alzheimer’s drug Leqembi

Growing demand has convinced Biogen that it's worth expanding the sales force around Leqembi by 30%.

BioPharma Dive 21 hours ago

BIIB
+4.56%
Biogen cost cuts drive profit beat, as Alzheimer's drug off to slow start

(Reuters) -Biogen reported a quarterly profit that topped Wall Street estimates, helped by cost cutting, as the launch of its new Alzheimer's disease drug remained sluggish. Sales of Alzheimer's drug Leqembi, recorded by Japanese partner Eisai, were just $19 million for the quarter, compared to analysts' tempered expectations of between $13 million and $30 million. However, the cost cutting measures contributed to a profit that exceeded analysts' expectations by 22 cents and Biogen shares were up nearly 5%.

Reuters 22 hours ago

BIIB
+4.56%
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump

Biogen beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series of cost-cutting measures as older drugs face fierce competition. The company also said its Alzheimer's drug Leqembi, developed with Japanese partner Eisai, recorded global sales of about $19 million, nearly tripling from the fourth quarter of 2023. The number of patients on the therapy have increased nearly 2.5 times since the end of 2023, Biogen said.

Reuters 22 hours ago

BIIB
+4.56%
Should You Be Confident in Biogen (BIIB)?

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter 2024 investor letter. A copy of the same can be downloaded here. During the quarter the strategy returned 11.8% net of fees compared to the S&P 500’s 10.6% return. The outperformance of the portfolio can be attributed to selection and […]

Insider Monkey 2 days ago

BIIB
+4.56%
What's in Store for Biogen (BIIB) This Earnings Season?

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.

Zacks 5 days ago

BIIB
+4.56%

Performance Overview

Return	BIIB	S&P 500
YTD	-21.94%	+6.33%
1-Year	-31.29%	+22.70%
3-Year	-23.09%	+21.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biogen Inc. (BIIB)

Biogen stock rises on Q1 results, Alzheimer's drug sales

Q1 2024 Biogen Inc Earnings Call

Why Biogen Stock Leaped Nearly 5% Higher Today

Biogen Stock Surges After Two Notable Products Walloped Sales Expectations

Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings

Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

Biogen (BIIB) Q1 2024 Earnings Call Transcript

Biogen: Don’t expect any big acquisitions this year

Biogen Stock Rises After Earnings, Jump in Sales of Alzheimer’s Drug

Biogen Affirms Guidance After Mixed First Quarter

Alzheimer’s Drug Leqembi Sees Sales Pickup, Boosting Biogen Stock

Biogen Beats Estimates as Alzheimer’s Drug Gains Traction

Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Biogen Inc (BIIB) Q1 2024 Earnings: Mixed Results Amidst Strategic Growth Efforts

Biogen sees ‘encouraging’ trends for postpartum depression drug

Biogen to invest more in launch of Alzheimer’s drug Leqembi

Biogen cost cuts drive profit beat, as Alzheimer's drug off to slow start

Biogen beats quarterly profit estimates, Alzheimer's drug sales jump

Should You Be Confident in Biogen (BIIB)?

What's in Store for Biogen (BIIB) This Earnings Season?

Performance Overview